InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

- Current share price for ACL : $2.810

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$524 Appendix 4C - quarterly 29 Oct 2013 8:49AM $0.600 $2.810 risen by 368.33%
$524 Preliminary Final Report and Financial Statements 30 Aug 2013 2:11PM $0.415 $2.810 risen by 577.11%
$524 Record Fondaparinux Quarterly Profit Share 20 Aug 2013 8:25AM $0.415 $2.810 risen by 577.11%
$524 Appendix 4C - quarterly 30 Jul 2013 9:35AM $0.355 $2.810 risen by 691.55%
$524 Response to ASX Price Query 17 Jun 2013 8:47AM $0.305 $2.810 risen by 821.31%
$524 Company Update 22 May 2013 8:27AM $0.375 $2.810 risen by 649.33%
$524 VAST US Patent Granted 1 May 2013 8:25AM $0.385 $2.810 risen by 629.87%
$524 Appendix 4C - quarterly 30 Apr 2013 8:18AM $0.385 $2.810 risen by 629.87%
$524 AstraZeneca Multi-Target Drug Discovery Collaboration 23 Apr 2013 8:27AM $0.350 $2.810 risen by 702.86%
$524 SPP Closes Heavily Oversubscribed 12 Apr 2013 8:29AM $0.345 $2.810 risen by 714.49%
$524 Launch of Fondaparinux in India 4 Apr 2013 9:10AM $0.325 $2.810 risen by 764.62%
$524 IP Update 4 Apr 2013 9:10AM $0.325 $2.810 risen by 764.62%
$524 Oversubscribed Placement and SPP 11 Mar 2013 8:45AM $0.380 $2.810 risen by 639.47%
$524 Trading Halt 6 Mar 2013 6:05PM $0.345 $2.810 risen by 714.49%
$524 Granted Key US Patent 6 Mar 2013 8:26AM $0.345 $2.810 risen by 714.49%
$524 S&P DJ Indices Announces March Quarterly Rebalance 1 Mar 2013 8:49AM $0.335 $2.810 risen by 738.81%
$524 Pivotal Phase III HA-Irinotecan Trial Enrolment Complete 28 Feb 2013 8:25AM $0.325 $2.810 risen by 764.62%
$524 Half Yearly Report and Accounts 27 Feb 2013 8:31AM $0.310 $2.810 risen by 806.45%
$524 R and D Tax Incentive Receipt 25 Feb 2013 9:21AM $0.325 $2.810 risen by 764.62%
$524 CEO Appointment 18 Feb 2013 8:29AM $0.335 $2.810 risen by 738.81%
$524 Fondaparinux Sales Update 18 Feb 2013 8:29AM $0.335 $2.810 risen by 738.81%
$524 Pivotal Phase III Study Full Patient Quota 4 Feb 2013 8:32AM $0.320 $2.810 risen by 778.13%
$524 CEO Departure 25 Jan 2013 6:30PM $0.310 $2.810 risen by 806.45%
$524 Appendix 4C - quarterly 25 Jan 2013 8:27AM $0.310 $2.810 risen by 806.45%
$524 Reinstatement to Official Quotation 21 Dec 2012 10:04AM $0.395 $2.810 risen by 611.39%

851 - 875 of 1023 results

Page 35 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.